Here are five things to know:
1. Located in Suzhou, the new facility is expected to begin operations in 2019 and will be the first time Johnson & Johnson produces minimally invasive surgical tools in a large overseas market.
2. The plant will focus on devices to treat lung cancer, liver cancer and gastric cancer.
3. Johnson & Johnson has had a presence in Suzhou since 2006, according to the report. The company also opened an innovation center in 2011 dedicated to the design and development of products for the Asian market.
4. When the new facility is complete, Johnson & Johnson plans to partner with local suppliers and improve technical and management standards.
5. The Chinese medical device market has grown around $55.8 million in the past year.
More articles on medical devices:
Smith & Nephew Q3 revenue jumps 3%: 5 things to know
ConforMIS saw revenue of $18.4M for Q3—7 observations
K2M sees $62.7M in Q3 revenue: 8 highlights
